Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy
Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of many malignancies. Ifosfamide-induced encephalopathy is one potential side effect that represents a major drawback to ifosfamide therapy and often necessitates discontinuation of chemotherapy. Previous reports demonstrate mo...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology pharmacy practice Jg. 25; H. 7; S. 1784 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
01.10.2019
|
| Schlagworte: | |
| ISSN: | 1477-092X, 1477-092X |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of many malignancies. Ifosfamide-induced encephalopathy is one potential side effect that represents a major drawback to ifosfamide therapy and often necessitates discontinuation of chemotherapy. Previous reports demonstrate moderate effectiveness of prophylactic methylene blue at thwarting ifosfamide-induced encephalopathy. This is a report of a 64-year-old female with relapsed double-hit diffuse large B-cell lymphoma who developed severe altered mental status and neurological symptoms after receiving a second dose of ifosfamide as part of her salvage standard dose R-IE (rituximab, ifosfamide, etoposide), in preparation for chimeric antigen receptor T-cell therapy. Ifosfamide was stopped and extensive metabolic and infectious workups, in addition to brain images, were all unremarkable. Her symptoms were attributed to ifosfamide. Prior to initiating cycle 2 of R-IE, she was started on prophylactic oral thiamine 100 mg, once a day, one week prior to her admission, methylene blue 50 mg intravenous every 6 h (for a total of four doses) and intravenous hydration with normal saline starting on day one of admission. Ifosfamide was administered in the standard dose 2000 mg/m
, days 1-3 as continuous intravenous infusion over 24 h. She tolerated the first two days of ifosfamide well and only developed mild encephalopathy during her last dose of ifosfamide. Her symptoms resolved completely without any intervention the following day and she completed all scheduled doses. She eventually received chimeric antigen receptor T-cell therapy. Our report demonstrates the use of hydration, methylene blue, and thiamine as a successful secondary prevention regimen for ifosfamide-induced encephalopathy. |
|---|---|
| AbstractList | Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of many malignancies. Ifosfamide-induced encephalopathy is one potential side effect that represents a major drawback to ifosfamide therapy and often necessitates discontinuation of chemotherapy. Previous reports demonstrate moderate effectiveness of prophylactic methylene blue at thwarting ifosfamide-induced encephalopathy. This is a report of a 64-year-old female with relapsed double-hit diffuse large B-cell lymphoma who developed severe altered mental status and neurological symptoms after receiving a second dose of ifosfamide as part of her salvage standard dose R-IE (rituximab, ifosfamide, etoposide), in preparation for chimeric antigen receptor T-cell therapy. Ifosfamide was stopped and extensive metabolic and infectious workups, in addition to brain images, were all unremarkable. Her symptoms were attributed to ifosfamide. Prior to initiating cycle 2 of R-IE, she was started on prophylactic oral thiamine 100 mg, once a day, one week prior to her admission, methylene blue 50 mg intravenous every 6 h (for a total of four doses) and intravenous hydration with normal saline starting on day one of admission. Ifosfamide was administered in the standard dose 2000 mg/m2, days 1-3 as continuous intravenous infusion over 24 h. She tolerated the first two days of ifosfamide well and only developed mild encephalopathy during her last dose of ifosfamide. Her symptoms resolved completely without any intervention the following day and she completed all scheduled doses. She eventually received chimeric antigen receptor T-cell therapy. Our report demonstrates the use of hydration, methylene blue, and thiamine as a successful secondary prevention regimen for ifosfamide-induced encephalopathy.Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of many malignancies. Ifosfamide-induced encephalopathy is one potential side effect that represents a major drawback to ifosfamide therapy and often necessitates discontinuation of chemotherapy. Previous reports demonstrate moderate effectiveness of prophylactic methylene blue at thwarting ifosfamide-induced encephalopathy. This is a report of a 64-year-old female with relapsed double-hit diffuse large B-cell lymphoma who developed severe altered mental status and neurological symptoms after receiving a second dose of ifosfamide as part of her salvage standard dose R-IE (rituximab, ifosfamide, etoposide), in preparation for chimeric antigen receptor T-cell therapy. Ifosfamide was stopped and extensive metabolic and infectious workups, in addition to brain images, were all unremarkable. Her symptoms were attributed to ifosfamide. Prior to initiating cycle 2 of R-IE, she was started on prophylactic oral thiamine 100 mg, once a day, one week prior to her admission, methylene blue 50 mg intravenous every 6 h (for a total of four doses) and intravenous hydration with normal saline starting on day one of admission. Ifosfamide was administered in the standard dose 2000 mg/m2, days 1-3 as continuous intravenous infusion over 24 h. She tolerated the first two days of ifosfamide well and only developed mild encephalopathy during her last dose of ifosfamide. Her symptoms resolved completely without any intervention the following day and she completed all scheduled doses. She eventually received chimeric antigen receptor T-cell therapy. Our report demonstrates the use of hydration, methylene blue, and thiamine as a successful secondary prevention regimen for ifosfamide-induced encephalopathy. Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of many malignancies. Ifosfamide-induced encephalopathy is one potential side effect that represents a major drawback to ifosfamide therapy and often necessitates discontinuation of chemotherapy. Previous reports demonstrate moderate effectiveness of prophylactic methylene blue at thwarting ifosfamide-induced encephalopathy. This is a report of a 64-year-old female with relapsed double-hit diffuse large B-cell lymphoma who developed severe altered mental status and neurological symptoms after receiving a second dose of ifosfamide as part of her salvage standard dose R-IE (rituximab, ifosfamide, etoposide), in preparation for chimeric antigen receptor T-cell therapy. Ifosfamide was stopped and extensive metabolic and infectious workups, in addition to brain images, were all unremarkable. Her symptoms were attributed to ifosfamide. Prior to initiating cycle 2 of R-IE, she was started on prophylactic oral thiamine 100 mg, once a day, one week prior to her admission, methylene blue 50 mg intravenous every 6 h (for a total of four doses) and intravenous hydration with normal saline starting on day one of admission. Ifosfamide was administered in the standard dose 2000 mg/m , days 1-3 as continuous intravenous infusion over 24 h. She tolerated the first two days of ifosfamide well and only developed mild encephalopathy during her last dose of ifosfamide. Her symptoms resolved completely without any intervention the following day and she completed all scheduled doses. She eventually received chimeric antigen receptor T-cell therapy. Our report demonstrates the use of hydration, methylene blue, and thiamine as a successful secondary prevention regimen for ifosfamide-induced encephalopathy. |
| Author | Powers, Benjamin C Gharaibeh, Eyad Z Salacz, Michael E Telfah, Mohammad |
| Author_xml | – sequence: 1 givenname: Eyad Z surname: Gharaibeh fullname: Gharaibeh, Eyad Z organization: Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA – sequence: 2 givenname: Mohammad surname: Telfah fullname: Telfah, Mohammad organization: Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA – sequence: 3 givenname: Benjamin C surname: Powers fullname: Powers, Benjamin C organization: Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA – sequence: 4 givenname: Michael E surname: Salacz fullname: Salacz, Michael E organization: Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30348070$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1LxDAQxYOsuB969yQ5ethqkjZN9ijL6goLXhS8lTSZuJE2rUkr7H9vFlfwMjMMv3m8eXM08Z0HhK4puaNUiHtKhKScMyolkXlJz9CMFkJkZMXeJ__mKZrH-EkIkYLJCzTNSV5IIsgMwfZgghpc55e4hWF_aMADrpsRllh5g4e9U61LKxWxwn2Ab_BHGgf4cC14bLuAne2iTZiBzHkzajAYvIZ-r5quV0n0Ep1b1US4OvUFenvcvK632e7l6Xn9sMt0kdMh47khRNdaltraknNhC1bI0gCXgttjkYZKnb5N7pmxclUUdTrluhak1Iwt0O2vbh-6rxHiULUuamga5aEbY8WoWKWwSkYTenNCx7oFU_XBtSocqr9o2A8DamgW |
| CitedBy_id | crossref_primary_10_3389_fphar_2025_1512966 crossref_primary_10_1186_s13569_020_00147_3 crossref_primary_10_1007_s00280_019_03949_5 crossref_primary_10_1007_s40278_019_68950_8 crossref_primary_10_1177_1078155220963545 crossref_primary_10_3390_cancers17132192 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1177/1078155218808361 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1477-092X |
| ExternalDocumentID | 30348070 |
| Genre | Journal Article |
| GroupedDBID | --- -TM .2E .2F .2G .2J .2N 01A 0R~ 18M 1~K 29L 31R 31S 31U 31X 31Y 31Z 36B 4.4 53G 54M 5GY 5VS 6PF 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8R4 8R5 AABMB AACKU AACMV AACTG AADUE AAEJI AAEWN AAGGD AAGLT AAGMC AAJIQ AAJOX AAJPV AAJQC AAKGS AANSI AAPEO AAPII AAQDB AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAWTL AAXOT AAYTG AAZBJ ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHKI ABHQH ABIDT ABJNI ABJZC ABKRH ABLUO ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABUWG ABVFX ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFO ACGFS ACGZU ACIWK ACJER ACJTF ACLFY ACLHI ACLZU ACOFE ACOXC ACPRK ACROE ACRPL ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEBD ADEIA ADMPF ADNBR ADNMO ADNON ADRRZ ADSTG ADTBJ ADUKL ADVBO ADYCS ADZZY AECGH AECVZ AEDTQ AEKYL AEPTA AEQLS AERKM AESZF AEUHG AEWDL AEWHI AEXFG AEXNY AFEET AFKBI AFKRA AFKRG AFMOU AFQAA AFRAH AFUIA AFWMB AGHKR AGKLV AGNHF AGPXR AGQPQ AGWFA AGWNL AHBZF AHDMH AHHFK AHMBA AIEWD AIGRN AJABX AJEFB AJGYC AJMMQ AJSCY AJUZI AJVBE AJXAJ ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV ASPBG AUTPY AUVAJ AVWKF AYAKG AZFZN AZQEC B3H B8M B8O B8R B8Z B93 B94 BBRGL BDDNI BENPR BKEYQ BKIIM BKSCU BMSDO BPACV BPHCQ BSEHC BVXVI BWJAD C45 CAG CBRKF CCPQU CDWPY CFDXU COF CORYS CQQTX CS3 CUTAK DB0 DC- DC. DC0 DD- DD0 DE- DF. DF0 DO- DOPDO DV7 DV9 DWQXO D~Y EBS EJD EX3 F5P FEDTE FHBDP FYUFA GNUQQ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GUQSH H13 HF~ HMCUK HVGLF HZ~ J5H J8X K.F K.J M1P M2O N9A NAPCQ NPM O9- OVD P.B P2P PADUT PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q1R Q2X Q7K Q7L Q7R Q7U Q7X Q82 Q83 ROL S01 SASJQ SAUOL SCNPE SDB SFB SFC SFK SFN SFT SGA SGO SGP SGR SGV SGX SGZ SHG SNB SPJ SPQ SPV SQCSI STM TEORI UKHRP WOW ZONMY ZPPRI ZRKOI ZSSAH 7X8 AJHME |
| ID | FETCH-LOGICAL-c431t-53d00cbc86cff6557f42486de5875f58758d18c1884802df8944bc435cb706c22 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000482977300037&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1477-092X |
| IngestDate | Sun Sep 28 02:44:03 EDT 2025 Mon Jul 21 05:50:14 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | thiamine methylene blue ifosfamide encephalopathy Cancer |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c431t-53d00cbc86cff6557f42486de5875f58758d18c1884802df8944bc435cb706c22 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| PMID | 30348070 |
| PQID | 2179218621 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2179218621 pubmed_primary_30348070 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-10-01 |
| PublicationDateYYYYMMDD | 2019-10-01 |
| PublicationDate_xml | – month: 10 year: 2019 text: 2019-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Journal of oncology pharmacy practice |
| PublicationTitleAlternate | J Oncol Pharm Pract |
| PublicationYear | 2019 |
| SSID | ssj0008728 |
| Score | 2.1865144 |
| Snippet | Ifosfamide is an alkylating chemotherapeutic agent used in the treatment of many malignancies. Ifosfamide-induced encephalopathy is one potential side effect... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1784 |
| Title | Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30348070 https://www.proquest.com/docview/2179218621 |
| Volume | 25 |
| WOSCitedRecordID | wos000482977300037&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7eEF-8zNu8EUH2tGDapWn6JCKKDzr2MGFvI82FCdpOO4X-e89pO_okCL4EWgiU9Ms5X3KS7yPkyjsd6YHUzBpnGC4gmE6cY0mEbNp6HepKZ_YpHg7VZJKMmg23ojlWuYyJVaC2ucE98mugzgn6J4XBzfyDoWsUVlcbC41Vsj4AKoOojietWriKK2_VQMQx40k4acuUECxihepjKEemBjL4nWBWieZh57-fuEu2G4pJb2tM7JEVl3XI5nNTRO-Q3qiWqy77dNzevir6tEdHrZB1uU_cY2lrgPQpOk2XkKEcTd--XJ_qzNLFDG-FwytdUE3njRhUnlF0e3h3GQVCTF99XuAuinUMlv8AJEsxmMxn-i1HO-TygLw83I_vHlljy8AMsI0FiwaWc5MaJY33MopiL0KhpHURrH08NsoGysDICsVD61UiRApdI5PGXJowPCRrWZ65Y0LhITBB4gEiWnCh00B6qYQXAfeSG9Ull8uRngLssZahM5d_FdN2rLvkqP5d03mtzzGFrIwX5fnJH3qfki2gQEl9PO-MrHuY9O6cbJjvxWvxeVHhCdrh6PkHwa_Vfg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hydration%2C+methylene+blue%2C+and+thiamine+as+a+prevention+regimen+for+ifosfamide-induced+encephalopathy&rft.jtitle=Journal+of+oncology+pharmacy+practice&rft.au=Gharaibeh%2C+Eyad+Z&rft.au=Telfah%2C+Mohammad&rft.au=Powers%2C+Benjamin+C&rft.au=Salacz%2C+Michael+E&rft.date=2019-10-01&rft.eissn=1477-092X&rft.volume=25&rft.issue=7&rft.spage=1784&rft_id=info:doi/10.1177%2F1078155218808361&rft_id=info%3Apmid%2F30348070&rft_id=info%3Apmid%2F30348070&rft.externalDocID=30348070 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-092X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-092X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-092X&client=summon |